Janet L Wang, MD
Hematology/Oncology · Santa Cruz
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: 057007 · 051526 · Dominican Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Wang’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A120525 · Current
Licensed to practise in California · since 2012 · expires 2027-08-31 · Baylor College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$5,350,728
Medicare paid this office $5,350,728 for 1,038 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, pembrolizumab, 1 mg | 29 | $1,073,984 | None |
| Injection, nivolumab, 1 mg | 12 | $369,393 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12 | $325,064 | None |
| Injection, vedolizumab, intravenous, 1 mg | 15 | $151,328 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 20 | $147,751 | None |
See all 58 services
| Injection, pembrolizumab, 1 mg | 29 | $1,073,984 | None |
| Injection, nivolumab, 1 mg | 12 | $369,393 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 12 | $325,064 | None |
| Injection, vedolizumab, intravenous, 1 mg | 15 | $151,328 | None |
| Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 20 | $147,751 | None |
| Injection, denosumab, 1 mg | 18 | $140,045 | None |
| Injection, tocilizumab, 1 mg | 22 | $138,017 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $122,561 | None |
| Injection, golimumab, 1 mg, for intravenous use | 28 | $96,879 | None |
| Return visit (30+ min) | 314 | $72,743 | $104 |
| Administration of chemotherapy into vein, 1 hour or less | 158 | $69,645 | $119 |
| Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 22 | $55,050 | $109 |
| Long return visit (40+ min) | 127 | $50,758 | $152 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 18 | $44,240 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 255 | $34,246 | $56 |
| Short return visit (20+ min) | 208 | $19,471 | $70 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $15,200 | None |
| Bcg live intravesical instillation, 1 mg | 43 | $11,636 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 27 | $11,271 | $66 |
| Instillation of anti-cancer drug into bladder | 45 | $8,181 | $77 |
| Administration of additional new drug or substance into vein, 1 hour or less | 47 | $7,363 | $58 |
| Injection of additional new drug or substance into vein | 96 | $6,827 | $14 |
| Administration of chemotherapy into vein using push technique | 11 | $5,917 | $90 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 29 | $5,647 | $0 |
| New patient visit (60+ min) | 28 | $5,228 | $187 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 55 | $5,111 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 49 | $5,101 | $18 |
| Administration of chemotherapy into vein, each additional hour | 55 | $4,622 | $25 |
| Collection of blood sample from implanted device | 60 | $4,492 | $25 |
| Injection, iron dextran, 50 mg | 15 | $4,163 | None |
| Injection of drug or substance under skin or into muscle | 101 | $4,009 | $13 |
| New patient visit (30+ min) | 39 | $3,474 | $89 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 80 | $3,344 | $14 |
| Injection, zoledronic acid, 1 mg | 102 | $2,759 | None |
| Administration of additional new drug or substance into vein using push technique | 24 | $2,604 | $50 |
| Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 15 | $2,530 | $0 |
| Injection of drug or substance into vein | 52 | $2,417 | $32 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 27 | $2,065 | $32 |
| Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg | 11 | $2,020 | None |
| New patient visit (45+ min) | 15 | $1,987 | $132 |
| Infusion into a vein for hydration, 31-60 minutes | 28 | $1,899 | $29 |
| Drawing of blood for a medical problem | 16 | $1,528 | $90 |
| Injection, fosaprepitant, 1 mg | 31 | $1,336 | None |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 35 | $1,056 | $18 |
| Irrigation of implanted venous access drug delivery device | 18 | $912 | $22 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 30 | $819 | $20 |
| Injection, carboplatin, 50 mg | 13 | $629 | None |
| Injection, fluorouracil, 500 mg | 11 | $619 | None |
| Infusion into a vein for hydration, each additional hour | 18 | $421 | $11 |
| Injection, paclitaxel, 1 mg | 12 | $401 | None |
| Injection, methylprednisolone sodium succinate, 5 mg | 18 | $299 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 55 | $204 | None |
| Infusion, normal saline solution , 1000 cc | 32 | $198 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 63 | $159 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 49 | $86 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 22 | $72 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 11 | $69 | None |
| Unclassified drugs | 17 | $19 | None |
Who their Medicare patients are
1,038 Original Medicare patients in 2024. Average age 75 · Under 65 5% · 85 and older 13% · Women 65% · Also on Medicaid 12% · Health risk score 1.59. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 62% · Cancer 42% · Chronic kidney disease 21% · Coronary heart disease 20% · Depression 20% · Diabetes 19% · Atrial fibrillation 18% · Heart failure 14% · COPD 12% · Stroke 4% · Dementia 3%.
The office billed $17,953,345, Medicare allowed $6,733,578 and paid $5,350,728; for 304,624 services of 169 kinds; $5,004,961 of it was for drugs given in the office and $345,766 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,038 | 304,624 | 75 | 1.59 | $17,953,345 | $5,350,728 |
| 2023 | 915 | 231,428 | 75 | 1.57 | $14,034,837 | $4,304,181 |
| 2022 | 852 | 181,296 | 75 | 1.59 | $9,953,937 | $3,183,306 |
| 2021 | 755 | 165,003 | 75 | 1.64 | $8,543,537 | $2,980,953 |
| 2020 | 755 | 192,708 | 74 | 1.64 | $10,717,361 | $3,697,772 |
| 2019 | 792 | 190,134 | 74 | 1.65 | $9,914,248 | $3,239,705 |
| 2018 | 757 | 191,670 | 73 | 1.72 | $9,468,768 | $2,828,071 |
| 2017 | 646 | 161,661 | 74 | 1.69 | $7,912,971 | $2,395,797 |
| 2016 | 581 | 113,985 | 73 | 1.65 | $5,849,990 | $1,723,398 |
| 2015 | 565 | 61,101 | 73 | 1.56 | $4,379,598 | $1,374,730 |
| 2014 | 456 | 42,516 | 73 | 1.56 | $2,968,490 | $799,714 |
| 2013 | 354 | 37,277 | 72 | 1.43 | $3,129,536 | $783,668 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 53 services
| Injection, pembrolizumab, 1 mg | 29 | $909,903 | None |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 15 | $681,464 | None |
| Injection, denosumab, 1 mg | 20 | $109,064 | None |
| Injection, vedolizumab, intravenous, 1 mg | 12 | $99,783 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 14 | $88,338 | None |
| Return visit (30+ min) | 325 | $83,902 | $105 |
| Administration of chemotherapy into vein, 1 hour or less | 153 | $69,529 | $125 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 17 | $67,588 | $22 |
| Injection, golimumab, 1 mg, for intravenous use | 16 | $47,460 | None |
| Injection, tocilizumab, 1 mg | 12 | $38,955 | None |
| Long return visit (40+ min) | 129 | $37,649 | $149 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 214 | $26,647 | $61 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 13 | $25,889 | $29 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $13,000 | $70 |
| Short return visit (20+ min) | 135 | $11,681 | $72 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $11,485 | None |
| New patient visit (60+ min) | 43 | $8,168 | $190 |
| Bcg live intravesical instillation, 1 mg | 33 | $7,718 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 35 | $7,175 | $61 |
| Injection of additional new drug or substance into vein | 75 | $6,575 | $14 |
| Instillation of anti-cancer drug into bladder | 36 | $5,689 | $79 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 11 | $5,683 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 51 | $5,618 | $27 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 21 | $5,513 | $0 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 52 | $5,144 | $19 |
| Cyclophosphamide, 100 mg | 12 | $5,030 | None |
| Collection of blood sample from implanted device | 44 | $4,200 | $25 |
| Administration of chemotherapy into vein, each additional hour | 54 | $3,763 | $26 |
| Administration of additional new drug or substance into vein using push technique | 19 | $3,728 | $53 |
| New patient visit (30+ min) | 42 | $3,727 | $89 |
| Injection, zoledronic acid, 1 mg | 73 | $2,985 | None |
| Injection of drug or substance under skin or into muscle | 85 | $2,701 | $13 |
| Infusion into a vein for hydration, 31-60 minutes | 26 | $2,160 | $30 |
| Injection of drug or substance into vein | 40 | $2,078 | $35 |
| New patient visit (45+ min) | 13 | $1,895 | $146 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 25 | $1,722 | $32 |
| Drawing of blood for a medical problem | 16 | $1,695 | $89 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 39 | $1,232 | $21 |
| Injection, fosaprepitant, 1 mg | 24 | $1,144 | None |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 13 | $1,108 | $0 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 21 | $790 | $18 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $764 | None |
| Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg | 12 | $701 | None |
| Infusion into a vein for hydration, each additional hour | 37 | $688 | $12 |
| Irrigation of implanted venous access drug delivery device | 20 | $658 | $23 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 14 | $306 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 52 | $216 | None |
| Infusion, normal saline solution , 1000 cc | 35 | $196 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 49 | $185 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 40 | $118 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 15 | $28 | None |
| Unclassified drugs | 12 | $12 | None |
| Infusion, normal saline solution, 250 cc | 15 | $11 | None |
2022: 49 services
| Injection, pembrolizumab, 1 mg | 26 | $596,022 | None |
| Injection, nivolumab, 1 mg | 13 | $263,538 | None |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 13 | $109,380 | None |
| Injection, denosumab, 1 mg | 22 | $86,801 | None |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 17 | $83,464 | $36 |
| Return visit (30+ min) | 281 | $70,578 | $102 |
| Administration of chemotherapy into vein, 1 hour or less | 160 | $57,290 | $132 |
| Injection, golimumab, 1 mg, for intravenous use | 11 | $48,972 | None |
| Injection, tocilizumab, 1 mg | 11 | $43,127 | None |
| Long return visit (40+ min) | 112 | $28,603 | $152 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 185 | $25,643 | $64 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 15 | $14,203 | $7 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 15 | $13,627 | None |
| Short return visit (20+ min) | 119 | $10,435 | $71 |
| Injection, iron dextran, 50 mg | 31 | $8,433 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 18 | $7,872 | $73 |
| Administration of additional new drug or substance into vein, 1 hour or less | 37 | $7,320 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 57 | $6,763 | $29 |
| Injection of additional new drug or substance into vein | 90 | $5,961 | $15 |
| Cyclophosphamide, 100 mg | 11 | $5,939 | None |
| New patient visit (60+ min) | 28 | $5,479 | $196 |
| Collection of blood sample from implanted device | 65 | $4,952 | $26 |
| Administration of chemotherapy into vein, each additional hour | 59 | $4,383 | $28 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 50 | $3,806 | $20 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 26 | $3,781 | $0 |
| Bcg live intravesical instillation, 1 mg | 21 | $3,581 | None |
| Instillation of anti-cancer drug into bladder | 24 | $2,914 | $81 |
| New patient visit (45+ min) | 20 | $2,892 | $145 |
| New patient visit (30+ min) | 30 | $2,887 | $96 |
| Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | 15 | $2,665 | $178 |
| Injection of drug or substance under skin or into muscle | 86 | $2,492 | $13 |
| Administration of additional new drug or substance into vein using push technique | 14 | $2,150 | $54 |
| Drawing of blood for a medical problem | 16 | $2,051 | $98 |
| Infusion into a vein for hydration, 31-60 minutes | 16 | $1,989 | $32 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $1,574 | $31 |
| Injection, zoledronic acid, 1 mg | 49 | $1,316 | None |
| Injection, fosaprepitant, 1 mg | 28 | $1,186 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 45 | $1,134 | $21 |
| Injection, paclitaxel, 1 mg | 17 | $913 | None |
| Irrigation of implanted venous access drug delivery device | 22 | $773 | $23 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 15 | $693 | None |
| Injection, carboplatin, 50 mg | 15 | $649 | None |
| Injection of drug or substance into vein | 12 | $452 | $38 |
| Injection, dexamethasone sodium phosphate, 1 mg | 53 | $150 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 56 | $150 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 20 | $148 | None |
| Infusion, normal saline solution , 1000 cc | 17 | $135 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 58 | $114 | None |
| Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise | 15 | $0 | $0 |
2021: 41 services
| Injection, pembrolizumab, 1 mg | 27 | $564,689 | None |
| Injection, denosumab, 1 mg | 22 | $102,353 | None |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 11 | $97,813 | $51 |
| Return visit (30+ min) | 278 | $70,779 | $106 |
| Administration of chemotherapy into vein, 1 hour or less | 122 | $61,517 | $139 |
| Injection, golimumab, 1 mg, for intravenous use | 11 | $36,581 | None |
| Long return visit (40+ min) | 119 | $29,575 | $149 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 153 | $22,662 | $68 |
| Short return visit (20+ min) | 127 | $11,992 | $67 |
| Injection, iron dextran, 50 mg | 34 | $10,019 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 46 | $7,309 | $30 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 13 | $6,267 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 22 | $6,048 | $67 |
| Collection of blood sample from implanted device | 63 | $5,377 | $25 |
| Injection of additional new drug or substance into vein | 61 | $4,639 | $16 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 18 | $4,587 | $0 |
| New patient visit (60+ min) | 24 | $4,528 | $189 |
| Administration of chemotherapy into vein, each additional hour | 39 | $3,848 | $29 |
| Infusion into a vein for hydration, 31-60 minutes | 26 | $3,536 | $33 |
| Administration of additional new drug or substance into vein using push technique | 13 | $3,474 | $58 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 15 | $3,313 | $77 |
| Bcg live intravesical instillation, 1 mg | 22 | $3,193 | None |
| New patient visit (45+ min) | 20 | $2,522 | $126 |
| Instillation of anti-cancer drug into bladder | 23 | $2,377 | $82 |
| Injection, zoledronic acid, 1 mg | 43 | $2,331 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 29 | $2,129 | $20 |
| Injection of drug or substance under skin or into muscle | 66 | $2,016 | $13 |
| Injection, fosaprepitant, 1 mg | 14 | $1,949 | None |
| New patient visit (30+ min) | 20 | $1,750 | $88 |
| Drawing of blood for a medical problem | 15 | $1,548 | $81 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 39 | $951 | $20 |
| Injection, paclitaxel, 1 mg | 13 | $852 | None |
| Injection of drug or substance into vein | 14 | $780 | $39 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $762 | $29 |
| Irrigation of implanted venous access drug delivery device | 12 | $681 | $25 |
| Injection, carboplatin, 50 mg | 12 | $561 | None |
| Infusion, normal saline solution , 1000 cc | 28 | $239 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 39 | $205 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 42 | $165 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 33 | $86 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 12 | $70 | None |
2020: 50 services
| Injection, pembrolizumab, 1 mg | 33 | $791,679 | None |
| Injection, nivolumab, 1 mg | 11 | $302,101 | None |
| Injection, rituximab, 10 mg | 13 | $158,756 | None |
| Injection, pegfilgrastim, 6 mg | 20 | $140,459 | None |
| Injection, denosumab, 1 mg | 22 | $106,399 | None |
| Administration of chemotherapy into vein, 1 hour or less | 154 | $82,327 | $130 |
| Return visit (30+ min) | 275 | $65,569 | $86 |
| Short return visit (20+ min) | 183 | $19,503 | $60 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 115 | $15,875 | $66 |
| Cyclophosphamide, 100 mg | 11 | $10,651 | None |
| Injection, fosaprepitant, 1 mg | 19 | $9,403 | None |
| Injection, iron dextran, 50 mg | 24 | $7,434 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 69 | $7,270 | $28 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 13 | $6,685 | $7 |
| Administration of additional new drug or substance into vein, 1 hour or less | 36 | $6,520 | $63 |
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 20 | $6,379 | $0 |
| Injection of additional new drug or substance into vein | 85 | $6,321 | $15 |
| Administration of chemotherapy into vein, each additional hour | 55 | $5,699 | $28 |
| Collection of blood sample from implanted device | 77 | $5,597 | $23 |
| New patient visit (60+ min) | 33 | $5,576 | $169 |
| Administration of additional new drug or substance into vein using push technique | 21 | $4,651 | $55 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $3,978 | $74 |
| Injection, alteplase recombinant, 1 mg | 11 | $3,487 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 32 | $3,486 | $20 |
| Injection of drug or substance under skin or into muscle | 75 | $2,939 | $13 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,612 | $119 |
| Instillation of anti-cancer drug into bladder | 24 | $2,591 | $70 |
| Infusion into a vein for hydration, 31-60 minutes | 29 | $2,487 | $31 |
| Long return visit (40+ min) | 18 | $2,322 | $122 |
| New patient visit (45+ min) | 20 | $2,259 | $113 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 24 | $2,116 | None |
| Bcg live intravesical instillation, 1 mg | 18 | $2,069 | None |
| New patient visit (30+ min) | 22 | $2,010 | $91 |
| Drawing of blood for a medical problem | 16 | $1,848 | $92 |
| Injection, zoledronic acid, 1 mg | 29 | $1,715 | None |
| Telephone medical discussion with physician, 11-20 minutes | 21 | $1,651 | $66 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 48 | $1,332 | $20 |
| Telephone medical discussion with physician, 5-10 minutes | 27 | $1,131 | $40 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,068 | $63 |
| Injection, doxorubicin hydrochloride, 10 mg | 11 | $762 | None |
| Injection of drug or substance into vein | 17 | $731 | $37 |
| Irrigation of implanted venous access drug delivery device | 18 | $666 | $23 |
| Injection, paclitaxel, 1 mg | 14 | $614 | None |
| Application of on-body injector for under skin injection | 12 | $475 | $18 |
| Injection, dexamethasone sodium phosphate, 1 mg | 59 | $223 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 67 | $214 | None |
| Infusion, normal saline solution , 1000 cc | 38 | $196 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 13 | $140 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 48 | $84 | None |
| Insertion of needle into vein for collection of blood sample | 14 | $47 | $3 |
2019: 47 services
| Injection, pembrolizumab, 1 mg | 27 | $546,912 | None |
| Injection, rituximab, 10 mg | 14 | $182,532 | None |
| Injection, pegfilgrastim, 6 mg | 11 | $159,554 | None |
| Injection, denosumab, 1 mg | 21 | $119,113 | None |
| Return visit (30+ min) | 426 | $104,550 | $87 |
| Administration of chemotherapy into vein, 1 hour or less | 143 | $73,810 | $129 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 11 | $21,023 | None |
| Injection, tbo-filgrastim, 1 microgram | 25 | $15,999 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 126 | $14,235 | $65 |
| Injection, fosaprepitant, 1 mg | 21 | $13,717 | None |
| New patient visit (60+ min) | 55 | $9,038 | $164 |
| Injection of additional new drug or substance into vein | 101 | $7,959 | $15 |
| Injection, iron dextran, 50 mg | 27 | $7,517 | None |
| New patient visit (45+ min) | 54 | $6,766 | $125 |
| Administration of chemotherapy into vein, each additional hour | 54 | $6,670 | $28 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $6,644 | $63 |
| Short return visit (20+ min) | 93 | $6,567 | $64 |
| Collection of blood sample from implanted device | 69 | $5,766 | $23 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 52 | $5,442 | $28 |
| Infusion into a vein for hydration, 31-60 minutes | 41 | $4,903 | $35 |
| Drawing of blood for a medical problem | 25 | $4,700 | $89 |
| Injection of drug or substance under skin or into muscle | 77 | $4,410 | $15 |
| Administration of additional new drug or substance into vein using push technique | 23 | $4,040 | $54 |
| Long return visit (40+ min) | 28 | $4,020 | $122 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,949 | $113 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $3,514 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $3,077 | $62 |
| Administration of chemotherapy into vein using push technique | 12 | $2,096 | $100 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 68 | $2,033 | $20 |
| Injection, zoledronic acid, 1 mg | 39 | $1,924 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 66 | $1,819 | $8 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 23 | $1,543 | $19 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $1,541 | None |
| Injection, paclitaxel, 1 mg | 17 | $1,166 | None |
| Injection of drug or substance into vein | 19 | $1,156 | $35 |
| Injection, carboplatin, 50 mg | 15 | $785 | None |
| Irrigation of implanted venous access drug delivery device | 23 | $782 | $24 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $760 | $27 |
| Injection, doxorubicin hydrochloride, 10 mg | 11 | $613 | None |
| Infusion into a vein for hydration, each additional hour | 15 | $475 | $12 |
| Injection, ondansetron hydrochloride, per 1 mg | 65 | $319 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 70 | $306 | None |
| Infusion, normal saline solution , 1000 cc | 45 | $288 | None |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 17 | $234 | None |
| Insertion of needle into vein for collection of blood sample | 24 | $97 | $3 |
| Injection, diphenhydramine hcl, up to 50 mg | 49 | $92 | None |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 13 | $33 | None |
2018: 45 services
| Injection, pembrolizumab, 1 mg | 16 | $285,129 | None |
| Injection, rituximab, 100 mg | 24 | $245,919 | None |
| Injection, pegfilgrastim, 6 mg | 20 | $139,355 | None |
| Injection, denosumab, 1 mg | 20 | $114,970 | None |
| Return visit (30+ min) | 405 | $93,953 | $83 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12 | $71,726 | None |
| Administration of chemotherapy into vein, 1 hour or less | 149 | $71,579 | $125 |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $61,945 | None |
| New patient visit (60+ min) | 83 | $13,795 | $166 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 114 | $12,822 | $63 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 17 | $9,359 | $1 |
| Injection of additional new drug or substance into vein | 107 | $9,217 | $16 |
| New patient visit (45+ min) | 73 | $9,210 | $126 |
| Administration of additional new drug or substance into vein, 1 hour or less | 40 | $8,481 | $60 |
| Injection, tbo-filgrastim, 1 microgram | 20 | $7,524 | None |
| Administration of chemotherapy into vein, each additional hour | 60 | $6,842 | $27 |
| Injection, fosaprepitant, 1 mg | 11 | $5,683 | None |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $5,403 | $71 |
| Long return visit (40+ min) | 37 | $5,379 | $120 |
| Administration of additional new drug or substance into vein using push technique | 23 | $4,676 | $52 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 147 | $4,493 | $9 |
| Infusion into a vein for hydration, 31-60 minutes | 35 | $4,387 | $40 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $4,048 | $112 |
| Injection of drug or substance under skin or into muscle | 68 | $4,019 | $18 |
| Drawing of blood for a medical problem | 20 | $3,075 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $2,942 | $60 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 46 | $2,809 | $28 |
| Injection, iron dextran, 50 mg | 12 | $2,653 | None |
| Administration of chemotherapy into vein using push technique | 15 | $2,527 | $97 |
| Injection, zoledronic acid, 1 mg | 46 | $2,262 | None |
| Injection of drug or substance into vein | 41 | $1,855 | $40 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 61 | $1,410 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 16 | $1,108 | $19 |
| Injection, paclitaxel, 1 mg | 21 | $1,107 | None |
| Collection of blood sample from implanted device | 28 | $1,100 | $22 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 11 | $1,089 | None |
| Injection, carboplatin, 50 mg | 25 | $1,000 | None |
| Infusion into a vein for hydration, each additional hour | 26 | $693 | $12 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $679 | $26 |
| Injection, iron sucrose, 1 mg | 12 | $661 | None |
| Insertion of needle into vein for collection of blood sample | 75 | $417 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 78 | $279 | None |
| Infusion, normal saline solution, 250 cc | 45 | $243 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 59 | $225 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 59 | $87 | None |
2017: 43 services
| Injection, rituximab, 100 mg | 22 | $217,372 | None |
| Injection, nivolumab, 1 mg | 11 | $141,041 | None |
| Injection, pembrolizumab, 1 mg | 13 | $137,289 | None |
| Injection, pegfilgrastim, 6 mg | 23 | $133,343 | None |
| Injection, denosumab, 1 mg | 21 | $109,487 | None |
| Return visit (30+ min) | 353 | $89,490 | $81 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 11 | $74,365 | None |
| Administration of chemotherapy into vein, 1 hour or less | 134 | $64,819 | $117 |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $47,877 | None |
| New patient visit (60+ min) | 81 | $13,472 | $166 |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 14 | $12,199 | None |
| Injection, tbo-filgrastim, 1 microgram | 26 | $10,799 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 94 | $9,984 | $58 |
| Injection of additional new drug or substance into vein | 100 | $9,346 | $19 |
| Infusion into a vein for hydration, 31-60 minutes | 31 | $9,311 | $49 |
| New patient visit (45+ min) | 64 | $8,453 | $132 |
| Administration of additional new drug or substance into vein, 1 hour or less | 44 | $8,132 | $56 |
| Injection, fosaprepitant, 1 mg | 13 | $6,559 | None |
| Long return visit (40+ min) | 41 | $6,352 | $115 |
| Injection of drug or substance under skin or into muscle | 83 | $5,521 | $22 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 131 | $5,288 | $10 |
| Injection, iron dextran, 50 mg | 22 | $5,100 | None |
| Administration of chemotherapy into vein, each additional hour | 51 | $4,150 | $24 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 34 | $3,909 | $112 |
| Administration of additional new drug or substance into vein using push technique | 19 | $3,432 | $53 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $3,201 | $64 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 44 | $2,472 | $26 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 15 | $2,278 | None |
| Drawing of blood for a medical problem | 17 | $1,983 | $79 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,769 | $59 |
| Biopsy of bone marrow | 12 | $1,581 | $132 |
| Injection, zoledronic acid, 1 mg | 32 | $1,500 | None |
| Infusion into a vein for hydration, each additional hour | 20 | $1,287 | $13 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 13 | $1,114 | $16 |
| Injection, carboplatin, 50 mg | 21 | $1,086 | None |
| Injection, paclitaxel, 1 mg | 19 | $1,056 | None |
| Injection of drug or substance into vein | 15 | $1,030 | $49 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $545 | $26 |
| Infusion, normal saline solution, 250 cc | 48 | $418 | None |
| Insertion of needle into vein for collection of blood sample | 74 | $400 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 67 | $261 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 55 | $184 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 49 | $73 | None |
2016: 39 services
| Injection, pegfilgrastim, 6 mg | 20 | $144,693 | None |
| Injection, denosumab, 1 mg | 12 | $116,548 | None |
| Injection, nivolumab, 1 mg | 12 | $113,985 | None |
| Injection, rituximab, 100 mg | 13 | $97,231 | None |
| Return visit (30+ min) | 299 | $86,032 | $83 |
| Administration of chemotherapy into vein, 1 hour or less | 105 | $39,819 | $105 |
| Long return visit (40+ min) | 57 | $10,795 | $117 |
| Injection, tbo-filgrastim, 1 microgram | 22 | $10,168 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 92 | $9,918 | $58 |
| New patient visit (45+ min) | 70 | $8,792 | $126 |
| Injection of additional new drug or substance into vein | 91 | $8,727 | $19 |
| New patient visit (60+ min) | 52 | $8,561 | $165 |
| Cyclophosphamide, 100 mg | 11 | $8,261 | None |
| Injection, fosaprepitant, 1 mg | 18 | $8,206 | None |
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 12 | $7,842 | None |
| Administration of additional new drug or substance into vein, 1 hour or less | 42 | $6,530 | $53 |
| Infusion into a vein for hydration, 31-60 minutes | 35 | $6,464 | $48 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 43 | $4,948 | $110 |
| Injection of drug or substance under skin or into muscle | 66 | $4,876 | $21 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 125 | $3,577 | $10 |
| Injection, iron dextran, 50 mg | 19 | $3,574 | None |
| Injection, zoledronic acid, 1 mg | 41 | $3,421 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,963 | $58 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 37 | $2,735 | $26 |
| Injection of drug or substance into vein | 30 | $2,324 | $47 |
| Administration of chemotherapy into vein, each additional hour | 34 | $2,283 | $24 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 22 | $1,880 | $15 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 12 | $1,808 | None |
| Biopsy of bone marrow | 11 | $1,556 | $141 |
| Administration of additional new drug or substance into vein using push technique | 15 | $1,415 | $52 |
| Injection, paclitaxel, 1 mg | 26 | $1,314 | None |
| Infusion into a vein for hydration, each additional hour | 30 | $1,112 | $13 |
| Injection, carboplatin, 50 mg | 20 | $1,042 | None |
| Infusion, normal saline solution, 250 cc | 51 | $316 | None |
| Insertion of needle into vein for collection of blood sample | 66 | $312 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 78 | $265 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 63 | $212 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 44 | $52 | None |
| Injection, magnesium sulfate, per 500 mg | 13 | $36 | None |
2015: 33 services
| Injection, rituximab, 100 mg | 19 | $174,390 | None |
| Injection, pegfilgrastim, 6 mg | 21 | $115,520 | None |
| Return visit (30+ min) | 254 | $72,261 | $87 |
| Injection, infliximab, excludes biosimilar, 10 mg | 11 | $50,616 | None |
| Administration of chemotherapy into vein, 1 hour or less | 87 | $33,933 | $112 |
| Injection, tbo-filgrastim, 5 micrograms | 32 | $14,470 | None |
| Long return visit (40+ min) | 69 | $12,936 | $121 |
| New patient visit (45+ min) | 89 | $12,197 | $137 |
| Injection, zoledronic acid, 1 mg | 63 | $11,496 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 85 | $8,632 | $61 |
| Injection of additional new drug or substance into vein | 75 | $7,657 | $20 |
| New patient visit (60+ min) | 43 | $7,624 | $177 |
| Infusion into a vein for hydration, 31-60 minutes | 34 | $6,186 | $50 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 35 | $4,780 | $117 |
| Administration of additional new drug or substance into vein, 1 hour or less | 30 | $4,103 | $55 |
| Injection of drug or substance under skin or into muscle | 68 | $3,782 | $22 |
| Administration of chemotherapy into vein, each additional hour | 36 | $3,589 | $25 |
| Injection, iron dextran, 50 mg | 16 | $3,235 | None |
| Injection of drug or substance into vein | 43 | $3,016 | $49 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 106 | $2,935 | $10 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,653 | $62 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 19 | $1,861 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 27 | $1,843 | $27 |
| Injection, paclitaxel, 1 mg | 23 | $1,597 | None |
| Administration of additional new drug or substance into vein using push technique | 11 | $1,425 | $55 |
| Injection, carboplatin, 50 mg | 14 | $941 | None |
| Infusion into a vein for hydration, each additional hour | 31 | $807 | $13 |
| Insertion of needle into vein for collection of blood sample | 87 | $535 | $3 |
| Infusion, normal saline solution, 250 cc | 46 | $217 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 52 | $175 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 45 | $110 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 44 | $60 | None |
| Unclassified drugs | 14 | $12 | None |
2014: 38 services
| Injection, rituximab, 100 mg | 15 | $125,021 | None |
| Injection, pegfilgrastim, 6 mg | 20 | $106,638 | None |
| Return visit (30+ min) | 222 | $62,884 | $81 |
| Administration of chemotherapy into vein, 1 hour or less | 69 | $20,922 | $77 |
| Injection, zoledronic acid, 1 mg | 39 | $14,318 | None |
| Cyclophosphamide, 100 mg | 12 | $10,061 | None |
| Injection, fosaprepitant, 1 mg | 14 | $8,297 | None |
| Injection of additional new drug or substance into vein | 65 | $7,822 | $19 |
| Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | 14 | $7,326 | None |
| Long return visit (40+ min) | 37 | $6,461 | $115 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 68 | $6,415 | $57 |
| New patient visit (45+ min) | 43 | $5,630 | $131 |
| New patient visit (30+ min) | 67 | $5,213 | $78 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 29 | $4,109 | $108 |
| Administration of additional new drug or substance into vein, 1 hour or less | 22 | $3,323 | $52 |
| Infusion into a vein for hydration, 31-60 minutes | 25 | $3,320 | $47 |
| Injection, iron dextran, 50 mg | 15 | $3,192 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 28 | $2,739 | $25 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,675 | $58 |
| Administration of chemotherapy into vein, each additional hour | 26 | $2,447 | $23 |
| Administration of additional new drug or substance into vein using push technique | 16 | $2,412 | $51 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 77 | $2,101 | $10 |
| Injection of drug or substance into vein | 24 | $2,072 | $47 |
| Injection of drug or substance under skin or into muscle | 45 | $2,027 | $21 |
| New patient visit (60+ min) | 12 | $2,007 | $167 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 22 | $1,972 | $15 |
| Injection, paclitaxel, 30 mg | 25 | $1,772 | None |
| Injection, carboplatin, 50 mg | 11 | $631 | None |
| Injection, doxorubicin hydrochloride, 10 mg | 11 | $619 | None |
| Infusion into a vein for hydration, each additional hour | 17 | $463 | $13 |
| Insertion of needle into vein for collection of blood sample | 68 | $382 | $3 |
| Irrigation of implanted venous access drug delivery device | 11 | $243 | $12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 50 | $212 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $199 | $17 |
| Injection, ondansetron hydrochloride, per 1 mg | 39 | $154 | None |
| Infusion, normal saline solution, 250 cc | 28 | $89 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 38 | $58 | None |
| Injection, ranitidine hydrochloride, 25 mg | 11 | $51 | None |
2013: 34 services
| Injection, rituximab, 100 mg | 21 | $234,349 | None |
| Injection, pegfilgrastim, 6 mg | 19 | $127,029 | None |
| Return visit (30+ min) | 158 | $47,649 | $84 |
| Administration of chemotherapy into vein, 1 hour or less | 70 | $18,414 | $75 |
| Injection, filgrastim (g-csf), 480 mcg | 14 | $17,867 | None |
| Cyclophosphamide, 100 mg | 17 | $17,326 | None |
| Long return visit (40+ min) | 40 | $7,759 | $116 |
| Injection, fosaprepitant, 1 mg | 14 | $6,692 | None |
| New patient visit (45+ min) | 52 | $6,635 | $128 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $6,289 | $60 |
| New patient visit (30+ min) | 75 | $6,232 | $83 |
| Injection of additional new drug or substance into vein | 59 | $6,214 | $19 |
| New patient visit (60+ min) | 30 | $4,802 | $160 |
| Administration of chemotherapy into vein, each additional hour | 34 | $4,620 | $26 |
| Injection, palonosetron hcl, 25 mcg | 11 | $4,219 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 38 | $2,927 | $27 |
| Administration of additional new drug or substance into vein using push technique | 18 | $2,795 | $53 |
| Irrigation of implanted venous access drug delivery device | 33 | $2,706 | $21 |
| Biopsy of bone marrow | 13 | $2,672 | $141 |
| Injection of drug or substance under skin or into muscle | 37 | $2,555 | $21 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $2,217 | $57 |
| Infusion into a vein for hydration, 31-60 minutes | 17 | $2,165 | $48 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 66 | $1,967 | $11 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,927 | $107 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 27 | $1,801 | $60 |
| Injection, doxorubicin hydrochloride, 10 mg | 16 | $1,192 | None |
| Injection, paclitaxel, 30 mg | 13 | $920 | None |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 15 | $782 | $18 |
| Insertion of needle into vein for collection of blood sample | 78 | $557 | $3 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $424 | $16 |
| Injection, ondansetron hydrochloride, per 1 mg | 48 | $276 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 56 | $172 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 31 | $53 | None |
| Infusion, normal saline solution , 1000 cc | 18 | $38 | None |
Medicaid work
$12,598 in 2024
Medicaid paid $12,598 for 211 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 60 | $6,376 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 77 | $4,408 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 74 | $1,814 |
| 2024 | 211 | 3 | 17 | $12,598 |
| 2023 | 272 | 3 | 27 | $23,421 |
| 2022 | 228 | 2 | 23 | $19,514 |
| 2021 | 260 | 2 | 24 | $18,469 |
| 2020 | 252 | 2 | 21 | $12,682 |
| 2019 | 471 | 4 | 40 | $26,878 |
| 2018 | 384 | 2 | 39 | $28,327 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 225 | $20,307 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 32 | $2,658 |
| Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour | 15 | $456 |
2022
| Return visit (30+ min) | 196 | $16,205 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 32 | $3,309 |
2021
| Return visit (30+ min) | 228 | $16,096 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 32 | $2,373 |
2020
| Return visit (30+ min) | 192 | $9,585 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 60 | $3,097 |
2019
| Return visit (30+ min) | 390 | $22,778 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 53 | $3,562 |
| Short return visit (20+ min) | 12 | $306 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure) | 16 | $232 |
2018
| Return visit (30+ min) | 365 | $26,270 |
| Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | 19 | $2,057 |
Drugs they prescribed that Part D paid
$2,672,916
Pharmacies billed $2,672,916 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (32 of 1,325) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
1,090 generic and fewer than 11 brand-name prescriptions · $2,672,916 in drug cost · 48 antibiotic prescriptions to 25 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Imbruvica | 53 | $739,855 | $13,960 |
| Ibrance | 23 | $366,592 | $15,939 |
| Jakafi | 17 | $296,846 | $17,462 |
| Lynparza | 17 | $253,354 | $14,903 |
| Revlimid | 11 | $235,466 | $21,406 |
See all 29 drugs
| Imbruvica | 53 | $739,855 | $13,960 |
| Ibrance | 23 | $366,592 | $15,939 |
| Jakafi | 17 | $296,846 | $17,462 |
| Lynparza | 17 | $253,354 | $14,903 |
| Revlimid | 11 | $235,466 | $21,406 |
| Lenalidomide | 17 | $193,180 | $11,364 |
| Everolimus | 19 | $175,295 | $9,226 |
| Abiraterone Acetate | 34 | $43,933 | $1,292 |
| Eliquis | 43 | $28,772 | $669 |
| Xarelto | 21 | $23,345 | $1,112 |
| Exemestane | 22 | $4,736 | $215 |
| Anastrozole | 116 | $2,574 | $22 |
| Imatinib Mesylate | 18 | $2,255 | $125 |
| Hydroxyurea | 71 | $1,981 | $28 |
| Letrozole | 54 | $1,822 | $34 |
| Tamoxifen Citrate | 67 | $1,702 | $25 |
| Dexamethasone | 46 | $1,684 | $37 |
| Acyclovir | 72 | $1,057 | $15 |
| Prochlorperazine Maleate | 65 | $923 | $14 |
| Ondansetron | 85 | $610 | $7 |
| Raloxifene | 11 | $602 | $55 |
| Diphenoxylate-Atropine | 14 | $533 | $38 |
| Gabapentin | 36 | $426 | $12 |
| Hydrocodone-Acetaminophen | 17 | $423 | $25 |
| Prednisone | 23 | $179 | $8 |
| Lidocaine-Prilocaine | 12 | $178 | $15 |
| Nystatin | 16 | $147 | $9 |
| Lorazepam | 23 | $138 | $6 |
| Sulfamethoxazole-Trimethoprim | 21 | $75 | $4 |
Year by year
| 2024 | 1,325 | 236 | 2% (32) | None | $2,672,916 |
| 2023 | 1,092 | 202 | 3% (32) | None | $2,211,243 |
| 2022 | 881 | 191 | 6% (51) | None | $1,567,622 |
| 2021 | 904 | 197 | 6% (57) | 20% | $1,736,723 |
| 2020 | 1,150 | 213 | 5% (56) | 23% | $2,198,389 |
| 2019 | 1,267 | 207 | 4% (53) | 18% | $2,186,041 |
| 2018 | 1,223 | 220 | 6% (70) | 16% | $1,643,294 |
| 2017 | 975 | 184 | 4% (43) | None | $647,040 |
| 2016 | 662 | 140 | 3% (18) | 20% | $448,516 |
| 2015 | 539 | 109 | 7% (36) | 22% | $643,883 |
| 2014 | 359 | 83 | 6% (23) | 25% | $550,534 |
| 2013 | 236 | 61 | 14% (33) | 26% | $249,013 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 28 drugs
| Imbruvica | 44 | $719,854 | $16,360 |
| Revlimid | 19 | $351,004 | $18,474 |
| Ibrance | 20 | $324,993 | $16,250 |
| Jakafi | 12 | $226,388 | $18,866 |
| Eliquis | 52 | $40,568 | $780 |
| Imatinib Mesylate | 14 | $32,434 | $2,317 |
| Abiraterone Acetate | 25 | $30,644 | $1,226 |
| Aromasin | 11 | $16,163 | $1,469 |
| Xarelto | 13 | $14,835 | $1,141 |
| Exemestane | 27 | $7,308 | $271 |
| Tamoxifen Citrate | 66 | $3,058 | $46 |
| Hydroxyurea | 72 | $2,619 | $36 |
| Anastrozole | 105 | $2,256 | $21 |
| Dexamethasone | 44 | $1,307 | $30 |
| Acyclovir | 62 | $1,263 | $20 |
| Prochlorperazine Maleate | 69 | $1,108 | $16 |
| Letrozole | 20 | $918 | $46 |
| Megestrol Acetate | 11 | $701 | $64 |
| Ondansetron Odt | 13 | $566 | $44 |
| Ondansetron | 60 | $558 | $9 |
| Raloxifene | 15 | $548 | $37 |
| Gabapentin | 24 | $454 | $19 |
| Prednisone | 41 | $425 | $10 |
| Hydrocodone-Acetaminophen | 12 | $277 | $23 |
| Lorazepam | 24 | $177 | $7 |
| Allopurinol | 12 | $123 | $10 |
| Ciprofloxacin | 12 | $75 | $6 |
| Sulfamethoxazole-Trimethoprim | 17 | $73 | $4 |
2022: 25 drugs
| Imbruvica | 29 | $443,383 | $15,289 |
| Revlimid | 18 | $328,660 | $18,259 |
| Ibrance | 18 | $263,946 | $14,664 |
| Jakafi | 12 | $213,608 | $17,801 |
| Imatinib Mesylate | 31 | $73,144 | $2,359 |
| Xarelto | 31 | $22,279 | $719 |
| Eliquis | 22 | $13,969 | $635 |
| Abiraterone Acetate | 12 | $7,450 | $621 |
| Exemestane | 21 | $2,871 | $137 |
| Tamoxifen Citrate | 54 | $2,683 | $50 |
| Anastrozole | 89 | $2,292 | $26 |
| Hydroxyurea | 57 | $2,010 | $35 |
| Dexamethasone | 51 | $1,589 | $31 |
| Raloxifene | 16 | $1,155 | $72 |
| Prochlorperazine Maleate | 64 | $1,044 | $16 |
| Acyclovir | 59 | $1,042 | $18 |
| Hydrocodone-Acetaminophen | 33 | $989 | $30 |
| Letrozole | 20 | $851 | $43 |
| Ondansetron | 31 | $755 | $24 |
| Gabapentin | 27 | $694 | $26 |
| Lidocaine-Prilocaine | 15 | $254 | $17 |
| Prednisone | 20 | $230 | $11 |
| Ciprofloxacin | 15 | $108 | $7 |
| Lorazepam | 16 | $65 | $4 |
| Sulfamethoxazole-Trimethoprim | 11 | $51 | $5 |
2021: 24 drugs
| Revlimid | 26 | $529,039 | $20,348 |
| Imbruvica | 44 | $498,031 | $11,319 |
| Ibrance | 11 | $151,217 | $13,747 |
| Imatinib Mesylate | 29 | $83,115 | $2,866 |
| Xarelto | 36 | $25,767 | $716 |
| Eliquis | 13 | $6,308 | $485 |
| Abiraterone Acetate | 16 | $5,779 | $361 |
| Exemestane | 19 | $5,419 | $285 |
| Anastrozole | 105 | $3,146 | $30 |
| Tamoxifen Citrate | 54 | $2,723 | $50 |
| Raloxifene | 23 | $2,703 | $118 |
| Hydroxyurea | 60 | $2,441 | $41 |
| Prochlorperazine Maleate | 58 | $1,152 | $20 |
| Acyclovir | 39 | $980 | $25 |
| Ondansetron | 38 | $963 | $25 |
| Hydrocodone-Acetaminophen | 24 | $948 | $40 |
| Oxycodone-Acetaminophen | 13 | $836 | $64 |
| Dexamethasone | 31 | $818 | $26 |
| Letrozole | 13 | $373 | $29 |
| Lidocaine-Prilocaine | 12 | $284 | $24 |
| Prednisone | 19 | $248 | $13 |
| Gabapentin | 16 | $226 | $14 |
| Lorazepam | 29 | $121 | $4 |
| Sulfamethoxazole-Trimethoprim | 16 | $31 | $2 |
2020: 28 drugs
| Revlimid | 41 | $777,118 | $18,954 |
| Imbruvica | 50 | $562,293 | $11,246 |
| Pomalyst | 11 | $213,433 | $19,403 |
| Xtandi | 12 | $160,950 | $13,412 |
| Imatinib Mesylate | 25 | $60,652 | $2,426 |
| Xarelto | 35 | $27,902 | $797 |
| Eliquis | 44 | $21,999 | $500 |
| Abiraterone Acetate | 15 | $10,590 | $706 |
| Exemestane | 34 | $8,816 | $259 |
| Tamoxifen Citrate | 76 | $3,697 | $49 |
| Hydroxyurea | 88 | $3,147 | $36 |
| Anastrozole | 128 | $3,089 | $24 |
| Raloxifene | 42 | $2,867 | $68 |
| Prochlorperazine Maleate | 80 | $1,688 | $21 |
| Famotidine | 16 | $1,047 | $65 |
| Ondansetron | 40 | $990 | $25 |
| Dexamethasone | 28 | $821 | $29 |
| Ondansetron Odt | 16 | $791 | $49 |
| Oxycodone-Acetaminophen | 16 | $723 | $45 |
| Acyclovir | 35 | $456 | $13 |
| Gabapentin | 25 | $361 | $14 |
| Hydrocodone-Acetaminophen | 13 | $348 | $27 |
| Letrozole | 20 | $323 | $16 |
| Prednisone | 23 | $281 | $12 |
| Lidocaine-Prilocaine | 14 | $232 | $17 |
| Lorazepam | 27 | $191 | $7 |
| Ciprofloxacin | 12 | $60 | $5 |
| Tramadol | 12 | $40 | $3 |
2019: 26 drugs
| Revlimid | 39 | $644,426 | $16,524 |
| Imbruvica | 25 | $308,551 | $12,342 |
| Pomalyst | 16 | $291,067 | $18,192 |
| Abiraterone Acetate | 13 | $95,689 | $7,361 |
| Imatinib Mesylate | 23 | $95,343 | $4,145 |
| Xarelto | 47 | $28,702 | $611 |
| Enoxaparin | 22 | $12,313 | $560 |
| Exemestane | 28 | $8,108 | $290 |
| Raloxifene | 54 | $7,280 | $135 |
| Tamoxifen Citrate | 121 | $5,641 | $47 |
| Anastrozole | 197 | $3,738 | $19 |
| Hydroxyurea | 74 | $2,462 | $33 |
| Oxycodone-Acetaminophen | 17 | $1,048 | $62 |
| Prochlorperazine Maleate | 69 | $1,005 | $15 |
| Dexamethasone | 36 | $943 | $26 |
| Ondansetron Odt | 20 | $927 | $46 |
| Ondansetron | 51 | $872 | $17 |
| Acyclovir | 48 | $710 | $15 |
| Lidocaine-Prilocaine | 28 | $568 | $20 |
| Prednisone | 45 | $458 | $10 |
| Morphine Sulfate Er | 13 | $423 | $33 |
| Gabapentin | 27 | $407 | $15 |
| Famotidine | 19 | $300 | $16 |
| Omeprazole | 13 | $230 | $18 |
| Lorazepam | 24 | $223 | $9 |
| Zolpidem | 14 | $56 | $4 |
2018: 26 drugs
| Imbruvica | 39 | $417,000 | $10,692 |
| Zytiga | 34 | $363,833 | $10,701 |
| Revlimid | 17 | $237,096 | $13,947 |
| Imatinib Mesylate | 11 | $84,613 | $7,692 |
| Xarelto | 49 | $24,441 | $499 |
| Raloxifene | 53 | $7,681 | $145 |
| Enoxaparin | 17 | $5,740 | $338 |
| Tamoxifen Citrate | 105 | $3,900 | $37 |
| Exemestane | 15 | $3,350 | $223 |
| Anastrozole | 200 | $3,238 | $16 |
| Hydroxyurea | 89 | $2,458 | $28 |
| Dexamethasone | 44 | $1,401 | $32 |
| Oxycodone-Acetaminophen | 12 | $713 | $59 |
| Ondansetron | 38 | $631 | $17 |
| Prochlorperazine Maleate | 78 | $608 | $8 |
| Prednisone | 57 | $594 | $10 |
| Ondansetron Odt | 20 | $563 | $28 |
| Morphine Sulfate Er | 21 | $408 | $19 |
| Acyclovir | 30 | $370 | $12 |
| Oxycodone | 14 | $348 | $25 |
| Gabapentin | 14 | $335 | $24 |
| Hydrocodone-Acetaminophen | 14 | $331 | $24 |
| Lorazepam | 74 | $311 | $4 |
| Lidocaine-Prilocaine | 14 | $264 | $19 |
| Zolpidem | 15 | $137 | $9 |
| Omeprazole | 15 | $114 | $8 |
2017: 19 drugs
| Revlimid | 13 | $171,305 | $13,177 |
| Imbruvica | 18 | $135,289 | $7,516 |
| Zytiga | 11 | $98,779 | $8,980 |
| Tarceva | 12 | $83,022 | $6,919 |
| Enoxaparin | 32 | $20,567 | $643 |
| Xarelto | 45 | $20,025 | $445 |
| Exemestane | 16 | $5,248 | $328 |
| Raloxifene | 39 | $3,399 | $87 |
| Tamoxifen Citrate | 79 | $3,236 | $41 |
| Hydroxyurea | 76 | $2,580 | $34 |
| Anastrozole | 167 | $2,387 | $14 |
| Ondansetron | 41 | $790 | $19 |
| Ondansetron Odt | 14 | $483 | $34 |
| Lidocaine-Prilocaine | 17 | $482 | $28 |
| Prochlorperazine Maleate | 72 | $461 | $6 |
| Lorazepam | 92 | $386 | $4 |
| Dexamethasone | 35 | $380 | $11 |
| Hydrocodone-Acetaminophen | 19 | $338 | $18 |
| Prednisone | 17 | $151 | $9 |
2016: 16 drugs
| Tarceva | 17 | $116,787 | $6,870 |
| Xarelto | 42 | $16,430 | $391 |
| Exemestane | 12 | $4,426 | $369 |
| Raloxifene | 19 | $3,111 | $164 |
| Doxycycline Hyclate | 12 | $2,454 | $204 |
| Tamoxifen Citrate | 68 | $1,455 | $21 |
| Anastrozole | 92 | $1,431 | $16 |
| Hydroxyurea | 37 | $955 | $26 |
| Ondansetron Odt | 20 | $754 | $38 |
| Prochlorperazine Maleate | 61 | $482 | $8 |
| Ondansetron | 41 | $471 | $11 |
| Dexamethasone | 24 | $281 | $12 |
| Mirtazapine | 23 | $227 | $10 |
| Gabapentin | 11 | $166 | $15 |
| Lorazepam | 15 | $125 | $8 |
| Prednisone | 14 | $95 | $7 |
2015: 15 drugs
| Revlimid | 20 | $232,844 | $11,642 |
| Gleevec | 12 | $121,558 | $10,130 |
| Xarelto | 21 | $7,099 | $338 |
| Doxycycline Hyclate | 17 | $2,778 | $163 |
| Anastrozole | 90 | $1,310 | $15 |
| Tamoxifen Citrate | 53 | $995 | $19 |
| Hydroxyurea | 40 | $880 | $22 |
| Morphine Sulfate Er | 15 | $530 | $35 |
| Ondansetron Odt | 13 | $527 | $41 |
| Dexamethasone | 17 | $373 | $22 |
| Ondansetron | 21 | $363 | $17 |
| Prochlorperazine Maleate | 34 | $260 | $8 |
| Lorazepam | 16 | $219 | $14 |
| Prednisone | 14 | $191 | $14 |
| Azithromycin | 14 | $117 | $8 |
2014: 10 drugs
| Revlimid | 21 | $219,735 | $10,464 |
| Imbruvica | 12 | $98,795 | $8,233 |
| Anastrozole | 78 | $1,989 | $26 |
| Tamoxifen Citrate | 24 | $381 | $16 |
| Hydroxyurea | 13 | $351 | $27 |
| Ondansetron | 13 | $319 | $25 |
| Prochlorperazine Maleate | 17 | $216 | $13 |
| Lorazepam | 20 | $185 | $9 |
| Prednisone | 13 | $177 | $14 |
| Dexamethasone | 23 | $173 | $8 |
2013: 7 drugs
| Revlimid | 13 | $115,008 | $8,847 |
| Enoxaparin | 17 | $25,120 | $1,478 |
| Anastrozole | 21 | $513 | $24 |
| Hydrocodone-Acetaminophen | 16 | $431 | $27 |
| Lorazepam | 16 | $124 | $8 |
| Dexamethasone | 11 | $88 | $8 |
| Zolpidem | 16 | $83 | $5 |
Money from drug and device companies
$112 in 2025
| 2025 | 4 | 5 | None | $112 |
| 2024 | 8 | 12 | None | $287 |
| 2023 | 1 | 1 | None | $26 |
| 2022 | 1 | 2 | None | $26 |
| 2021 | 1 | 2 | None | $24 |
| 2019 | 1 | 1 | None | $17 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| E.R. Squibb & Sons L.L.C. | Opdivo | $38 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $35 | 1 payment
|
| Janssen Biotech | Erleada | $21 | 1 payment
|
| Celgene | Reblozyl | $18 | 1 payment
|
See all 5 published payments
| AstraZeneca Pharmaceuticals LP | Education · 2025-11-19 | Imfinzi | $35 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-15 | Opdivo | $20 |
| Janssen Biotech | Meals · 2025-04-09 | Erleada | $21 |
| Celgene | Meals · 2025-02-11 | Reblozyl | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-04 | Opdivo | $18 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $287
| Celgene | Reblozyl | $62 | 3 payments
|
| GlaxoSmithKline | Jemperli | $55 | 2 payments
|
| Array Biopharma | Braftovi | $42 | 2 payments
|
| Amgen | Evenity | $40 | 1 payment
|
| Sumitomo Pharma America | Orgovyx | $25 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $24 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $24 | 1 payment
|
| Janssen Biotech | Erleada | $15 | 1 payment
|
2023: $26
| Janssen Biotech | None | $26 | 1 payment
|
2022: $26
| Acrotech Biopharma | Beleodaq | $26 | 2 payments
|
2021: $24
| Acrotech Biopharma | Beleodaq | $24 | 2 payments
|
2019: $17
| Stemline Therapeutics | Elzonris | $17 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme Corporation · A Randomized, Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 As Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 Cm Residual Invasive Cancer Or Positive Lymph Nodes Pn1mic After Neoadjuvant Chemotherapy · 2020 | Their institution | $96 |
Professional record
- NPI
- 1760629158
- Licence
- CA A120525California A120525: Current · expires 2027-08-31
- Trained
- Baylor College of Medicine, 2006
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2025 Soquel Ave., Santa Cruz, CA, 95062
- NPI first listed
- 2009-01-07
- NPI last updated
- 2012-09-19
This is when the NPI record was last certified, not a medical board exam.